Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells
- Authors:
- Keshab Raj Parajuli
- Younghun Jung
- Russell S. Taichman
-
Affiliations: Department of Periodontology, University of Alabama at Birmingham School of Dentistry, Birmingham, AL 35294, USA, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA - Published online on: January 8, 2024 https://doi.org/10.3892/or.2024.8698
- Article Number: 39
-
Copyright: © Parajuli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Taichman RS, Loberg RD, Mehra R and Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest. 117:2351–2361. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wenzel M, Garcia CC, Hoeh B, Jorias C, Humke C, Koll F, Tselis N, Rödel C, Graefen M, Tilki D, et al: Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy. Prostate. 83:1365–1372. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Rogowski P, Trapp C, von Bestenbostel R, Schmidt-Hegemann NS, Shi R, Ilhan H, Kretschmer A, Stief C, Ganswindt U, Belka C and Li M: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol. 16:1252021. View Article : Google Scholar : PubMed/NCBI | |
|
Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D and Angeli A: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 164:1248–1253. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sartor O and de Bono JS: Metastatic prostate cancer. N Engl J Med. 378:645–657. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Uhr JW and Pantel K: Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA. 108:12396–12400. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ruppender NS, Morrissey C, Lange PH and Vessella RL: Dormancy in solid tumors: Implications for prostate cancer. Cancer Metastasis Rev. 32:501–509. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Phan TG and Croucher PI: The dormant cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Aguirre-Ghiso JA, Estrada Y, Liu D and Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63:1684–1695. 2003.PubMed/NCBI | |
|
Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM and Aguirre-Ghiso JA: TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38α/β signalling. Nat Cell Biol. 15:1351–1361. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Prunier C, Baker D, Ten Dijke P and Ritsma L: TGF-β family signaling pathways in cellular dormancy. Trends Cancer. 5:66–78. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sosa MS, Avivar-Valderas A, Bragado P, Wen HC and Aguirre-Ghiso JA: ERK1/2 and p38α/β signaling in tumor cell quiescence: Opportunities to control dormant residual disease. Clin Cancer Res. 17:5850–5857. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yumoto K, Eber MR, Wang J, Cackowski FC, Decker AM, Lee E, Nobre AR, Aguirre-Ghiso JA, Jung Y and Taichman RS: Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep. 6:365202016. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, Pai SK, Liu W, Fukuda K, Chambers C, et al: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208:2641–2655. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Le Page-Degivry MT, Bidard JN, Rouvier E, Bulard C and Lazdunski M: Presence of abscisic acid, a phytohormone, in the mammalian brain. Proc Natl Acad Sci USA. 83:1155–118. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Bruzzone S, Ameri P, Briatore L, Mannino E, Basile G, Andraghetti G, Grozio A, Magnone M, Guida L, Scarfì S, et al: The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J. 26:1251–1260. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bruzzone S, Bodrato N, Usai C, Guida L, Moreschi I, Nano R, Antonioli B, Fruscione F, Magnone M, Scarfì S, et al: Abscisic acid is an endogenous stimulator of insulin release from human pancreatic islets with cyclic ADP ribose as second messenger. J Biol Chem. 283:32188–32197. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bruzzone S, Basile G, Mannino E, Sturla L, Magnone M, Grozio A, Salis A, Fresia C, Vigliarolo T, Guida L, et al: Autocrine abscisic acid mediates the UV-B-induced inflammatory response in human granulocytes and keratinocytes. J Cell Physiol. 227:2502–2510. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bruzzone S, Moreschi I, Usai C, Guida L, Damonte G, Salis A, Scarfì S, Millo E, De Flora A and Zocchi E: Abscisic acid is an endogenous cytokine in human granulocytes with cyclic ADP-ribose as second messenger. Proc Natl Acad Sci USA. 104:5759–5764. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Magnone M, Bruzzone S, Guida L, Damonte G, Millo E, Scarfì S, Usai C, Sturla L, Palombo D, De Flora A and Zocchi E: Abscisic acid released by human monocytes activates monocytes and vascular smooth muscle cell responses involved in atherogenesis. J Biol Chem. 284:17808–17818. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Magnone M, Sturla L, Jacchetti E, Scarfì S, Bruzzone S, Usai C, Guida L, Salis A, Damonte G, De Flora A and Zocchi E: Autocrine abscisic acid plays a key role in quartz-induced macrophage activation. FASEB J. 26:1261–1271. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Scarfi S, Ferraris C, Fruscione F, Fresia C, Guida L, Bruzzone S, Usai C, Parodi A, Millo E, Salis A, et al: Cyclic ADP-ribose-mediated expansion and stimulation of human mesenchymal stem cells by the plant hormone abscisic acid. Stem Cells. 26:2855–2864. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li HH, Hao RL, Wu SS, Guo PC, Chen CJ, Pan LP and Ni H: Occurrence, function and potential medicinal applications of the phytohormone abscisic acid in animals and humans. Biochem Pharmacol. 82:701–712. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sakthivel P, Sharma N, Klahn P, Gereke M and Bruder D: Abscisic Acid: A phytohormone and mammalian cytokine as novel pharmacon with potential for future development into clinical applications. Curr Med Chem. 23:1549–1570. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fresia C, Vigliarolo T, Guida L, Booz V, Bruzzone S, Sturla L, Di Bona M, Pesce M, Usai C, De Flora A and Zocchi E: G-protein coupling and nuclear translocation of the human abscisic acid receptor LANCL2. Sci Rep. 6:266582016. View Article : Google Scholar : PubMed/NCBI | |
|
Bassaganya-Riera J, Guri AJ, Lu P, Climent M, Carbo A, Sobral BW, Horne WT, Lewis SN, Bevan DR and Hontecillas R: Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 286:2504–2516. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Leber A, Hontecillas R, Zoccoli-Rodriguez V and Bassaganya-Riera J: Activation of LANCL2 by BT-11 Ameliorates IBD by supporting regulatory T cell stability through immunometabolic mechanisms. Inflamm Bowel Dis. 24:1978–1991. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 9:1–9. 2003.PubMed/NCBI | |
|
Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffler HP: Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 60:5494–5498. 2000.PubMed/NCBI | |
|
Sikka S, Chen L, Sethi G and Kumar AP: Targeting PPARγ signaling cascade for the prevention and treatment of prostate cancer. PPAR Res. 2012:9680402012. View Article : Google Scholar : PubMed/NCBI | |
|
Fizazi K and Navone NM: Preclinical models of prostate cancer. Bull Cancer. 92:129–141. 2005.(In French). PubMed/NCBI | |
|
Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S and Contag CH: Animal models of bone metastasis. Cancer. 97 (Suppl 3):S748–S57. 2003. View Article : Google Scholar | |
|
Chung LW, Kao C, Sikes RA and Zhau HE: Human prostate cancer progression models and therapeutic intervention. Hinyokika Kiyo. 43:815–820. 1997.PubMed/NCBI | |
|
Wang Y, Herroon MK, Zielske SP, Ellis L, Podgorski I, Taichman RS and Cackowski FC: Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis. J Bone Oncol. 30:1003862021. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, et al: A genetic screen for candidate tumor suppressors identifies REST. Cell. 121:837–848. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Chamberlain L, Pak ML, Nagarajan A, Gupta R, Zhu LJ, Wright CM, Fong KM, Wajapeyee N and Green MR: A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling. Cancer Discov. 4:1168–1181. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O and Uysal A: Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncol Lett. 7:2103–2109. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang Y, Hotchkin M, Lee E, Buttitta L and Taichman RS: Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow. Neoplasia. 23:102–111. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Xing F, Liu Y, Wu K, Said N, Pochampally R, Shiozawa Y, Lin HK, Balaji KC and Watabe K: Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem. 291:19351–19363. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG: Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI | |
|
Roudier MP, Corey E, True LD, Hiagno CS, Ott SM and Vessell RL: Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res. 118:311–339. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, et al: Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 17:3924–3932. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Viale PH: The American Cancer Society's facts & figures: 2020 edition. J Adv Pract Oncol. 11:135–136. 2020.PubMed/NCBI | |
|
Ku SY, Gleave ME and Beltran H: Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 16:645–654. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Patel VG and Oh WK: The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy. 11:903–912. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Takezawa D, Komatsu K and Sakata Y: ABA in bryophytes: How a universal growth regulator in life became a plant hormone? J Plant Res. 124:437–453. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lievens L, Pollier J, Goossens A, Beyaert R and Staal J: Abscisic acid as pathogen effector and immune regulator. Front Plant Sci. 8:5872017. View Article : Google Scholar : PubMed/NCBI | |
|
Sano N and Marion-Poll A: ABA metabolism and homeostasis in seed dormancy and germination. Int J Mol Sci. 22:50692021. View Article : Google Scholar : PubMed/NCBI | |
|
Chaqour J, Lee S, Ravichandra A and Chaqour B: Abscisic acid-an anti-angiogenic phytohormone that modulates the phenotypical plasticity of endothelial cells and macrophages. J Cell Sci. 131:jcs2104922018. View Article : Google Scholar : PubMed/NCBI | |
|
Baliño P, Gómez-Cadenas A, López-Malo D, Romero FJ and Muriach M: Is there a role for abscisic acid, a proven anti-inflammatory agent, in the treatment of ischemic retinopathies? Antioxidants (Basel). 8:1042019. View Article : Google Scholar : PubMed/NCBI | |
|
Sturla L, Fresia C, Guida L, Bruzzone S, Scarfì S, Usai C, Fruscione F, Magnone M, Millo E, Basile G, et al: LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells. J Biol Chem. 284:28045–28057. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cao LQ, Shao ZL, Liang HH, Zhang DW, Yang XW, Jiang XF and Xue P: Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression. Cancer Lett. 359:127–135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bolden A, Bernard L, Jones D, Akinyeke T and Stewart LV: The PPAR gamma agonist troglitazone regulates Erk 1/2 phosphorylation via a PPARγ-Independent, MEK-dependent pathway in human prostate cancer cells. PPAR Res. 2012:9290522012. View Article : Google Scholar : PubMed/NCBI | |
|
Cho SJ, Kook MC, Lee JH, Shin JY, Park J, Bae YK, Choi IJ, Ryu KW and Kim YW: Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. Int J Cancer. 136:810–820. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, et al: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology. 136:1242–1250. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA and Pestell RG: Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol. 21:3057–3070. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G, Kitagawa H, Kayahara M, Yamamoto M, Terada T and Miwa K: PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol. 17:1157–1164. 2000.PubMed/NCBI | |
|
Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M, Hosotani R and Imamura M: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 94:370–376. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Jabbar ZR and Sahib HB: The effects of abscisic acid on angiogenesis in both ex vivo and in vivo assays. Asian Pac J Cancer Prev. 23:4193–4203. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao HF, Zhou XM, Wang J, Chen FF, Wu CP, Diao PY, Cai LR, Chen L, Xu YW, Liu J, et al: Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. J Transl Med. 19:3722021. View Article : Google Scholar : PubMed/NCBI | |
|
Yousefnia S, Momenzadeh S, Seyed Forootan F, Ghaedi K and Nasr Esfahani MH: The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity. Gene. 649:14–22. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Spinelli S, Begani G, Guida L, Magnone M, Galante D, D'Arrigo C, Scotti C, Iamele L, De Jonge H, Zocchi E and Sturla L: LANCL1 binds abscisic acid and stimulates glucose transport and mitochondrial respiration in muscle cells via the AMPK/PGC-1α/Sirt1 pathway. Mol Metab. 53:1012632021. View Article : Google Scholar : PubMed/NCBI | |
|
Biagioni B, Tomei L, Valleriani C, Liccioli G, Barni S, Sarti L, Citera F, Giovannini M and Mori F: Allergy to Gibberellin-Regulated Proteins (Peamaclein) in Children. Int Arch Allergy Immunol. 182:1194–1199. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa M, Hanada M, Inomata N and Amano H: A case of a gibberellin-regulated protein-positive patient allergic to various fruits. Eur J Dermatol. 31:88–90. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Inuo C, Okazaki F, Shiraki R, Tanaka Y, Momma K, Kondo Y and Narita H: Generalized allergic reaction in response to exercise due to strawberry gibberellin-regulated protein: a case report. Allergy Asthma Clin Immunol. 18:492022. View Article : Google Scholar : PubMed/NCBI | |
|
Mo J, Kang M, Ye JX, Chen JB, Zhang HB and Qing C: Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Egbewande FA, Sadowski MC, Levrier C, Tousignant KD, White JM, Coster MJ, Nelson CC and Davis RA: Identification of gibberellic acid derivatives that deregulate cholesterol metabolism in prostate cancer cells. J Nat Prod. 81:838–845. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mukherjee A, Gaurav AK, Singh S, Yadav S, Bhowmick S, Abeysinghe S and Verma JP: The bioactive potential of phytohormones: A review. Biotechnol Rep (Amst). 35:e007482022. View Article : Google Scholar : PubMed/NCBI | |
|
Shuai HW, Meng YJ, Luo XF, Chen F, Qi Y, Yang WY and Shu K: The roles of auxin in seed dormancy and germination. Yi Chuan. 38:314–322. 2016.PubMed/NCBI | |
|
Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, Ekpin E, George A, Zheng Y, Lam HM, et al: NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes. Nat Commun. 6:61702015. View Article : Google Scholar : PubMed/NCBI | |
|
Chambard JC, Lefloch R, Pouysségur J and Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta. 1773:1299–1310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yu C, Shiozawa Y, Taichman RS, McCauley LK, Pienta K and Keller E: Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr. 22:131–148. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morrissey C, Vessella RL, Lange PH and Lam HM: The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med (Berl). 94:259–265. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cackowski FC and Taichman RS: Minimal residual disease in prostate cancer. Adv Exp Med Biol. 1100:47–53. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ and Taichman RS: GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 12:116–127. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, et al: Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia. 14:429–439. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jung Y, Decker AM, Wang J, Lee E, Kana LA, Yumoto K, Cackowski FC, Rhee J, Carmeliet P, Buttitta L, et al: Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget. 7:25698–25711. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cackowski FC and Taichman RS: Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation. Bone. 119:82–86. 2019. View Article : Google Scholar : PubMed/NCBI |
